Could this be the - plase? Tenecteplase or alteplase for acute ischemic stroke, part 1

Dr. James Braun, Neurosciences Pharmacy Clinical Specialist at SSM Health St. Louis, and Dr. Kyle Hoelting, Senior Manager of Drug Information at Vizient, share their insights on the use of tenecteplase vs alteplase for treating acute ischemic stroke. They also discuss the nuances of this therapeutic area and share recent work from an expert panel led by Vizient.

 

Guest speakers:
James Braun, PharmD, BCCCP
Neurosciences Pharmacy Clinical Specialist 
SSM Health

 

Kyle Hoelting, PharmD, BCPS
Senior Manager of Drug Information 
Vizient

 

Moderator:
Gretchen Brummel, PharmD, BCPS
Pharmacy Executive Director
Vizient Center for Pharmacy Practice Excellence

 

Show Notes:

[00:58-3:00] James’ background and his role in the treatment of stroke patients

[03:01-5:09] History of tenecteplase and alteplase for ischemic stroke

[05:10-6:56] Information about trials of alteplase

[06:57-8:11] Where Tenecteplase fits in discussion

[08:12-9:51] Differences with tenecteplase and alteplase to clinicians

[9:52-12:00] What studies say about potential, practical advantages of tenecteplase

[12:01-19:55] Making the switch between agents

 

Links | Resources:

Verified Rx: Evidenced based medicine Click here

Verified Rx: Show me the data! Updates on the evidence of thrombolytic use in ischemic strokes Click here

Verified Rx: Information overload: tips and tricks for staying on top of the literature, part 1 Click here

Verified Rx: Information overload: tips and tricks for staying on top of the literature, part 2 Click here

Identifying errors and safety considerations in patients undergoing thrombolysis in acute ischemic stroke Click here

EXTEND-IA TNK Click here

Australian-TNK Click here

Meta-analysis NIHSS outcomes Click here

NOR-TEST Click here

 

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Google Podcasts

Spotify

Stitcher

Android

RSS Feed